ArticleGland surgery2026
Prognostic impact of extensive nodal involvement in small-sized (T1) breast cancer: a population-based and propensity score-matched analysis of the SEER database.
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognostic significance of extensive nodal involvement (N2-3) in patients with small-sized (T1) breast cancer remains to be fully elucidated. This study aimed to compare the clinicopathological characteristics and survival outcomes between T1N0-1M0 and T1N2-3M0 breast cancer. Methods: Patients diagnosed with T1 breast cancer between 2010 and 2012 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Clinicopathological features were compared using Chi-squared tests and t-tests. Overall survival (OS) and breast cancer-specific survival (BCSS) were assessed using Kaplan-Meier analysis and Cox regression. Propensity score matching (PSM) was performed to minimize confounding effects. Competing risk analysis using the Fine-Gray model was also conducted to compare the cumulative incidence of breast cancer-specific death, accounting for death from other causes as a competing event. Results: Of 60,318 eligible patients with T1M0 breast cancer, 2.9% (n=1,772) had T1N2-3M0 disease. Compared to the T1N0-1M0 cohort, these patients were younger, had higher T substages, less frequent hormone receptor positivity, higher human epidermal growth factor receptor 2 (HER2) positivity and tumor grade, and received more aggressive surgical and systemic therapy (all P<0.001). Before matching, T1N2-3M0 status was associated with significantly worse 5-year OS [86.9% Conclusions: Even within T1 breast cancer, extensive nodal involvement (N2-3) defines a distinct subgroup with more aggressive tumor biology and significantly poorer survival, independent of other clinicopathological factors. This underscores the critical need for comprehensive nodal staging and potentially more intensive treatment strategies for T1N2-3 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.